VEVEY, Switzerland, Jan. 9, 2025 /PRNewswire/ -- Nescafé, the largest coffee brand globally, is launching its first-ever liquid espresso concentrate in the US, the biggest coffee market in the world[1]. With one out of every three cups of coffee consumed outside of the home being a cold coffee, Nescafé Espresso Concentrate allows consumers to make barista-style, personalized cold espresso beverages in the comfort of their home.
The growth of global coffee consumption is being driven by younger generations, and two out of three youth regularly drink cold coffee. In North America, 50% of Generation Z consumers' first cup of coffee is cold. Nescafé Espresso Concentrate answers this growing demand for customizable, convenient, at-home cold coffee. Because the concentrate easily dissolves in water or milk, consumers can simply mix it with ice and water or milk and then customize it to create their go-to drink, whether an iced mocha, macchiato, or cappuccino.
Axel Touzet, Head of Nestlé Coffee Brands Strategic Business Unit, said, "Through the Nescafé Espresso Concentrate we want to capture what younger generations of consumers are looking for: cold, convenient, customizable, premium coffee that brings the experience and taste they have outside their home to inside their home. We are enabling them to create café-style beverages in an instant without any extra machinery."
Nescafé Espresso Concentrate is made with 100% Arabica beans and comes in a 300-milliliter bottle (enough for approximately 20 cups of espresso when prepared as directed). In the US, it will be available at retailers starting in February in two variations: Nescafé Espresso Concentrate Black and Nescafé Espresso Concentrate Sweet Vanilla.
The Nescafé Espresso Concentrate was successfully launched last year in China and Australia.
[1] Source: Statista.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Nescafé Espresso Concentrate expands to the US: enabling consumers to create customized, café-style, cold espresso beverages at home
CAMBRIDGE, Mass. and BRUSSELS, Jan. 9, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license agreement on XtalFoldâ„¢, a biologics AI platform developed by Ailux Biologics, a division of XtalPi.
Under the agreement, Ailux Biologics grants UCB a non-exclusive license to leverage XtalFoldâ„¢ for the discovery and engineering of biologics. XtalFoldâ„¢ is a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases.
"UCB has long been a pioneer in leveraging computation to develop highly differentiated biologics that benefit patients." stated Jian Ma, CEO of XtalPi, "We are proud to contribute to their efforts in creating therapies that transform lives." Yi (Alex) Li, VP of XtalPi and Head of Ailux Biologics, said: "The recent Nobel Prize highlighted the groundbreaking impact of protein structure prediction. XtalFoldâ„¢ exemplifies this innovation, offering a commercially validated solution with rapid industry adoption. We're excited to join forces with UCB to further explore its potential."
XtalFoldâ„¢ utilizes sequence information alone to model the interaction between biomolecules, which forms the foundation of biotherapeutics like monoclonal antibodies. In rigorous benchmark studies, XtalFoldâ„¢ achieved state-of-the-art performance in terms of overall success rate and the quality of hard-to-model regions like the antibody-antigen interface. XtalFoldâ„¢ has been licensed to multiple global pharmaceutical companies and has delivered highly impactful results in a variety of projects, including antigen design, epitope identification, affinity maturation, pH-sensitivity engineering, and bispecifics design.
"UCB have a strong legacy of antibody discovery and engineering. We have established unique and powerful single-B cell screening and in vitro display discovery technologies to support hit identification and are pioneers in structure-based and computer-aided optimisation of molecules. The XtalFoldâ„¢ license takes this further, integrating antibody-antigen structural insights into the entire antibody discovery and optimisation workflow," said Daniel Lightwood, Head of Antibody Discovery and Optimisation. Alexander Hillisch, Head of Global CADD, UCB added, "Our decision to license this tool comes after extensive testing and evaluation against other computational approaches and we believe it has the potential to enhance UCB's ability to rapidly and efficiently discover high quality therapeutic antibody candidates and ultimately deliver new medicines to patients."
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
About XtalPi
XtalPi ("XtalPi Holdings Limited", stock code: 2228.HK) is a quantum physics-based, AI-powered, and robotics-driven, innovative R&D platform company. Established in 2015 by three physicists at Massachusetts Institute of Technology (MIT), the company is dedicated to driving intelligent and digital transformation in the life sciences and materials sciences sectors. XtalPi combines quantum physics, AI, cloud computing, and large-scale robotics to provide R&D solutions and services for biomedicine, chemical, renewable energy and advanced materials industries globally.
About Ailux Biologics
Ailux Biologics is a division of XtalPi ("XtalPi Holdings Limited", stock code: 2228.HK) dedicated to the innovation in large molecule drug discovery. With a team of around 100 experts, Ailux has established a state-of-the-art biologics discovery lab, a proprietary database purpose-built for AI (AtlaXâ„¢) and a trio of AI platforms, including a structure modeling suite (XtalFoldâ„¢), a generative large language model for proteins (XenProTâ„¢) and a predictive AI suite for biologics (Xentientâ„¢). Ailux partners with pharma and biotech companies to accelerate their biologics programs with AI-powered, lab-validated solutions. To learn more, visit https://ailuxbio.com/ and follow @Ailux Biologics on Linkedin.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
